In 2020, Richmond Pharmacology made history by becoming the first clinical research organisation to administer CRISPR-Cas9 gene-editing therapy to a human. Since then, we’ve established ourselves as the global leader in in-vivo gene-editing and base-editing clinical trials.

With unparalleled expertise in lipid nanoparticle (LNP) gene editing, Richmond has dosed more patients and initiated more first-in-human trials than any other clinic worldwide. Our commitment to advancing ground-breaking therapeutics underscores our position as the CRO of choice for precision medicine development.

Our sponsors are granted fast international marketing approvals due to our inclusive study design which fulfils the data requirements of global regulators.